✦ LIBER ✦

Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis Patients

✍ Scribed by Bruce Y. Lee; Randy M. Stalter; Kristina M. Bacon; Julie H.Y. Tai; Rachel R. Bailey; Shanta M. Zimmer; Michael M. Wagner

Book ID: 114470138
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 669 KB
Volume: 57
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2010.12.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIN15 COST EFFECTIVENESS OF MF59 ADJUVAN

PIN15 COST EFFECTIVENESS OF MF59 ADJUVANTED INFLUENZA VACCINE IN FRANCE

✍ J Chambers; I Eijgelshoven; J Piercy; S Wait 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

PIN8 COST EFFECTIVENESS OF THE MF59-ADJU

PIN8 COST EFFECTIVENESS OF THE MF59-ADJUVANTED INFLUENZA VACCINE IN FRANCE:THE “AT-RISK” ADULT POPULATION

✍ J Chambers; K Tolley; J Piercy; S Wait 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Vaccination versus treatment of influenz

Vaccination versus treatment of influenza in working adults: A cost-effectiveness analysis

✍ Michael B. Rothberg; David N. Rose 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Cost-effectiveness of influenza immuniza

Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan

✍ H-H. Lin; K-L. Hsu; W. W-C. Ko; Y-C. Yang; Y-W. Chang; M-C. Yu; K-T. Chen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB

Cost-effectiveness of live attenuated in

Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States

✍ Bryan R. Luce; Kristin L. Nichol; Robert B. Belshe; Kevin D. Frick; Su Xia Li; A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 327 KB

Cost-effectiveness of influenza vaccinat

Cost-effectiveness of influenza vaccination in working-age cancer patients

✍ Elenir B. C. Avritscher; Catherine D. Cooksley; Jane M. Geraci; Benjamin N. Beke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## BACKGROUND. Despite recommendations to immunize all patients at an increased risk of influenza complications, the vaccine utilization among high‐risk nonelderly adults remains low and its cost‐effectiveness is unclear. In the current study, the authors analyzed the cost‐effectivenes